- AutorIn
- Ph.D. Sukrit Mahajan Institute of Anatomy, Dresden University of Technology
- Titel
- EGFL7-driven immune evasion in malignant glioma: mechanistic insights and therapeutic implications
- Zitierfähige Url:
- https://nbn-resolving.org/urn:nbn:de:bsz:14-qucosa2-1043758
- Erstveröffentlichung
- 2026
- Datum der Einreichung
- 03.11.2025
- Datum der Verteidigung
- 17.03.2026
- Abstract (EN)
- Glioblastoma is the most aggressive form of malignant brain cancer, characterized by an immunosuppressive microenvironment and extensive angiogenesis. It accounts for approximately 50% of all primary central nervous system malignancies and 15% of all brain tumors. Moreover, it has an annual incidence of approximately 3.19 to 4.17 cases per 100,000 people. However, despite multimodal therapeutic interventions, including surgery, radiotherapy along with adjuvant chemotherapy, the prognosis for glioblastoma patients remains poor, largely due to the ability of the tumor to evade the immune response. In this context, the glioblastoma microenvironment (GME) plays an important role in inducing an immunosuppressive environment, thereby promoting tumor progression and providing resistance to conventional therapies. This highlights the importance of identifying novel and effective therapeutic strategies for countering glioblastoma. In this regard, epidermal growth factor-like protein 7 (EGFL7), a secreted pro-angiogenic factor, is highly expressed in the GME and has been shown to promote tumor vascularization and progression. Additionally, it has been implicated in immune escape by lung and breast cancers, however its role in immune regulation in glioblastoma has not been investigated. Therefore, in the current study, we investigated the impact of EGFL7 in shaping the immune landscape in glioblastoma and identified underlying mechanisms. Our findings show that EGFL7 promotes tumor progression in immunocompetent mice through its influence on the immune landscape in glioblastoma, which is abrogated in immunodeficient mice. Furthermore, single-cell transcriptomic profiling of immune cells from murine glioblastoma tissue revealed that EGFL7 expression promotes an immunosuppressive microenvironment characterized by increased frequency of anti-inflammatory tumor associated M2 macrophages and myeloid-derived suppressor cells, with a concurrent decrease in pro-inflammatory M1 macrophages. In addition, ectopic EGFL7 expression was associated with increased T cell exhaustion and higher frequency of regulatory T cells, which have been associated with immunosuppression in glioblastoma. Conversely, knockout of EGFL7 led to a reduction in lipid-associated M2 macrophages along with a concurrent increase in effector T cell populations. In addition, the spatial distribution of different immune cells in the glioma mass revealed that ectopic EGFL7 expression is associated with reduced infiltration of CD4+ and CD8+ T cells, with a concurrent increase in CD206+ anti-inflammatory M2 macrophages. Conversely, EGFL7 knockout led to an increase in CD4+ and CD8+ T cells, along with a reduction in CD206+ anti-inflammatory M2 macrophages. The influence of EGFL7 expression on different immune cell populations in vivo led us to investigate whether EGFL7 directly impacts the immune cell populations. For this, we employed purified EGFL7 protein and performed in vitro analysis of macrophage polarization and T cell function. Our investigation revealed that EGFL7 promotes polarization of macrophages into an M2 anti-inflammatory state as well as inhibits effector T cell function. Further analysis of these populations in human glioblastoma patients revealed that EGFL7 expression has a positive correlation with presence of M2 macrophages, exhausted T cells and regulatory T cells. Concurrently, we also observed a negative correlation with M1 macrophages. Thus, to elucidate the mechanism of EGFL7 function on immune cells, we performed mass spectrometry analysis of the EGFL7 interactome isolated from the tumor tissue of glioma bearing mice. Mass spectrometry and co-immunoprecipitation revealed that ITGB2, an immune cell receptor, interacts with EGFL7 within the GME. Mechanistic studies showed that EGFL7 inhibits T cell migration in vitro, which gets exacerbated upon inhibition of ITGB2. Moreover, EGFL7 and anti-ITGB2 treatment alone did not have a significant effect on migration of myeloid cell populations. However, a combination of purified EGFL7 and anti-ITGB2 antibody led to a sharp decline in the migration of CD11b+ myeloid cells. To functionally validate the influence of EGFL7-ITGB2 interaction, we genetically inactivated ITGB2 in immunocompetent mice and employed the gain-of-function study using GL261-DsRed and GL261-mEGFL7 tumor cells. Disrupting the EGFL7-ITGB2 interaction through knockout of ITGB2, led to a reduction in T cell exhaustion and M2 macrophages in mEGFL7-glioma bearing mice compared to the littermate control. Moreover, it prolonged the survival in hematopoietic stem cell specific ITGB2 knockout mice. Furthermore, the EGFL7-ITGB2 axis was targeted with an EGFL7 blocking antibody along with PD1 inhibition to reduce T cell exhaustion. This led to an increase in survival of glioblastoma-bearing mice and curbed tumor growth in both DsRed and mEGFL7-glioma bearing mice. Interestingly, anti-EGFL7 and anti-PD1 monotherapies had no effect on tumor growth and overall survival in glioma-bearing mice. This shows that targeting EGFL7, particularly in combination with inhibiting immunoregulatory molecules such as PD1, may enhance therapeutic efficacy in glioblastoma. Thus, this thesis provides unequivocal evidence that EGFL7 promotes immune evasion in glioblastoma through its interaction with ITGB2, and positions EGFL7-ITGB2 axis as a potential therapeutic target for reprogramming the immune system in glioblastoma. Moreover, the results provide a strong rationale for clinical evaluation of combinatorial therapies targeting EGFL7 and PD1 in glioblastoma patients. In conclusion, this thesis opens avenues for future research on other angiogenic factors and their potential role in remodeling the immune landscape in other solid tumors, besides glioblastoma. Moreover, elucidating the functional consequence of EGFL7-ITGB2 interaction challenges the traditional view that angiogenesis and immune evasion are distinct processes, and rather position them as convergent hallmarks of glioblastoma, which drive tumor progression.
- Freie Schlagwörter (DE)
- Glioblastom, Tumormikroumgebung, Immunflucht, scRNA-Sequenzierung, Immuntherapie
- Freie Schlagwörter (EN)
- Glioblastoma, tumor microenvironment, immune evasion, scRNA-sequencing, immunotherapy
- Klassifikation (DDC)
- 610
- Klassifikation (RVK)
- XH 8504
- GutachterIn
- Prof. Dr. Dr. Mirko HH Schmidt
- Prof. Dr. med. Hanno Glimm
- Den akademischen Grad verleihende / prüfende Institution
- Technische Universität Dresden, Dresden
- Version / Begutachtungsstatus
- publizierte Version / Verlagsversion
- URN Qucosa
- urn:nbn:de:bsz:14-qucosa2-1043758
- Veröffentlichungsdatum Qucosa
- 06.07.2026
- Dokumenttyp
- Dissertation
- Sprache des Dokumentes
- Englisch
- Lizenz / Rechtehinweis
CC BY 4.0